Browse result page of B3Pdb
The total number entries retrieved from this search are 318, scroll left/right for detailed information.
| B3pdbIDb3pdb_0001 | PEPTIDE NAMEMtfpep | PEPTIDE SEQUENCE (1-letter)DSSHAFTLDELR | PEPTIDE SEQUENCE (3-letter)AspSerSerHisAlaPheThrLeuAspGluLeuArg | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION Polyethylene glycol (PEG)4 linker | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH12 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEMelanotransferrin | SMILESN[C@@]([H])(CC(=O)O)C(=O)N[C@@]([H])(CO)C(=O)N[C@@]([H])(CO)C(=O)N[C@@]([H])(CC1=CN=C-N1)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(Cc1ccccc1)C(=O)N[C@@]([H])([C@]([H])(O)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(=O)O)C(=O)N[C@@]([H])(CCC(=O)O)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)O | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELMice | In vivo CONCENTRATION2 MTfpep per NIP228 antibody | In vivo MODE OF DELIVERYIntravenous | In vivo METHOD3D confocal fluorescence microscopy | In vivo RESULTTwo times greater fractional fluorescence was measured in the brain parenchyma. | ACTIONIt delivers a protein-based interleukin 1 receptor antagonist across the BBB and ameliorates | TRANSPORT TYPETranscytosis | SUBCELLULAR LOCALISATIONSurface of normal brain endothelial cells, the main constituent of the BBB, and is able to cross thr | COMBINATIONSuccessfully delivers therapeutic amounts of an an | PHYSICAL CONDITIONNeuropathic pain | RESPONSEStability/half life | RESULT5.5 days | LABELNA | PMID 29845881 |
| B3pdbIDb3pdb_0007 | PEPTIDE NAMED-T7 | PEPTIDE SEQUENCE (1-letter)HRPYIAHC | PEPTIDE SEQUENCE (3-letter)HisArgProTyrIleAlaHisCys | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION Cysteine on C-terminal | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH7 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESN[C@@]([H])(CC1=CN=C-N1)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N1[C@@]([H])(CCC1)C(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC1=CN=C-N1)C(=O)N[C@@]([H])(CS)C(=O)O | CELL LINEbEnd.3 and c6 cells | In vitro CONCENTRATIONNA | In vitro METHODConfocal microscopy | In vitro RESULTIt crosses the BBB. | ANIMAL MODELMice | In vivo CONCENTRATIONPTX-1.7 mg/kg, CD-3.6 mg/kg | In vivo MODE OF DELIVERYIntravenous | In vivo METHODNA | In vivo RESULTNA | ACTIOND-T7 Peptide Modified PEGylated Bilirubin Nanoparticles Loaded with Cediranib and Paclitaxel for Ant | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONCombined with Cediranib and Paclitaxel. | PHYSICAL CONDITIONGlioma | RESPONSEStability/half life | RESULT3.31-fold higher than saline | LABELNA | PMID 30525386 |
| B3pdbIDb3pdb_0008 | PEPTIDE NAMETransportan 10 | PEPTIDE SEQUENCE (1-letter)AGYLLGKINLKALAALAKKIL | PEPTIDE SEQUENCE (3-letter)AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION Amide group is attached | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH21 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURECationic | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESN[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O | CELL LINES. aureus MRSA N315 | In vitro CONCENTRATION100000 CFU/mL | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELBALB/c mice | In vivo CONCENTRATION60 mg/kg | In vivo MODE OF DELIVERYIntravenous | In vivo METHODFluorescence microscopy assay | In vivo RESULTIt crosses the BBB. | ACTIONIt shows intermediate susceptibility. | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONAlone | PHYSICAL CONDITIONNA | RESPONSEMIC | RESULT6.3 ± 1.3 micromolar | LABELNA | PMID 30824786 |
| B3pdbIDb3pdb_0009 | PEPTIDE NAMETransportan 10 | PEPTIDE SEQUENCE (1-letter)AGYLLGKINLKALAALAKKIL | PEPTIDE SEQUENCE (3-letter)AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu | N-TERMINAL MODIFICATIONN-terminal Fmoc group was removed and the propiola | C-TERMINAL MODIFICATION Amide group is attached | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH21 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURECationic | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESN[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O | CELL LINES. aureus MRSA N315 | In vitro CONCENTRATION100000 CFU/mL | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELBALB/c mice | In vivo CONCENTRATION60 mg/kg | In vivo MODE OF DELIVERYIntravenous | In vivo METHODFluorescence microscopy assay | In vivo RESULTIt crosses the BBB. | ACTIONIt shows intermediate susceptibility. | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONAlone | PHYSICAL CONDITIONNA | RESPONSEMIC | RESULT1.6 ± 0.9micromolar | LABELNA | PMID 30824786 |
| B3pdbIDb3pdb_0010 | PEPTIDE NAMETransportan 10 | PEPTIDE SEQUENCE (1-letter)AGYLLGKINLKALAALAKKIL | PEPTIDE SEQUENCE (3-letter)AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu | N-TERMINAL MODIFICATIONN-terminal Fmoc group was removed and the propiola | C-TERMINAL MODIFICATION Amide group is attached | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH21 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURECationic | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESN[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O | CELL LINES. aureus MRSA N315 | In vitro CONCENTRATION100000 CFU/mL | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELBALB/c mice | In vivo CONCENTRATION60 mg/kg | In vivo MODE OF DELIVERYIntravenous | In vivo METHODFluorescence microscopy assay | In vivo RESULTIt crosses the BBB. | ACTIONIt shows intermediate susceptibility. | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONAlone | PHYSICAL CONDITIONNA | RESPONSEMIC | RESULT1.6 ± 0.8 micromolar | LABELNA | PMID 30824786 |
| B3pdbIDb3pdb_0011 | PEPTIDE NAMETransportan 10 | PEPTIDE SEQUENCE (1-letter)AGYLLGKINLKALAALAKKIL | PEPTIDE SEQUENCE (3-letter)AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION Amide group is attached | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH21 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURECationic | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESN[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O | CELL LINES. aureus MRSA N315 | In vitro CONCENTRATION100000 CFU/mL | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELBALB/c mice | In vivo CONCENTRATION60 mg/kg | In vivo MODE OF DELIVERYIntravenous | In vivo METHODFluorescence microscopy assay | In vivo RESULTIt crosses the BBB. | ACTIONIt shows the resistance | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONAlone | PHYSICAL CONDITIONNA | RESPONSEMIC | RESULT12.5 ± 3.2 micromolar | LABELNA | PMID 30824786 |
| B3pdbIDb3pdb_0012 | PEPTIDE NAMETransportan 10 | PEPTIDE SEQUENCE (1-letter)AGYLLGKINLKALAALAKKIL | PEPTIDE SEQUENCE (3-letter)AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION Amide group is attached | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH21 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURECationic | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESN[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O | CELL LINES. aureus MRSA N315 | In vitro CONCENTRATION100000 CFU/mL | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELBALB/c mice | In vivo CONCENTRATION60 mg/kg | In vivo MODE OF DELIVERYIntravenous | In vivo METHODFluorescence microscopy assay | In vivo RESULTIt crosses the BBB. | ACTIONIt shows intermediate susceptibility. | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONAlone | PHYSICAL CONDITIONNA | RESPONSEMIC | RESULT6.3 ± 1.6 micromolar | LABELNA | PMID 30824786 |
| B3pdbIDb3pdb_0013 | PEPTIDE NAMETransportan 10 | PEPTIDE SEQUENCE (1-letter)AGYLLGKINLKALAALAKKIL | PEPTIDE SEQUENCE (3-letter)AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu | N-TERMINAL MODIFICATION6-carboxyfluorescein (Fl) was coupled to the N-ter | C-TERMINAL MODIFICATION Amide group is attached | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH21 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURECationic | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESN[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O | CELL LINES. aureus MRSA N315 | In vitro CONCENTRATION100000 CFU/mL | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELBALB/c mice | In vivo CONCENTRATION60 mg/kg | In vivo MODE OF DELIVERYIntravenous | In vivo METHODFluorescence microscopy assay | In vivo RESULTIt crosses the BBB. | ACTIONIt shows intermediate susceptibility. | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONAlone | PHYSICAL CONDITIONNA | RESPONSEMIC | RESULT6.3 ± 1.6 micromolar | LABELNA | PMID 30824786 |
| B3pdbIDb3pdb_0014 | PEPTIDE NAMETransportan 10 | PEPTIDE SEQUENCE (1-letter)AGYLLGKINLKALAALAKKIL | PEPTIDE SEQUENCE (3-letter)AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION Amide group is attached | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH21 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURECationic | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESN[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O | CELL LINES. aureus MRSA 12673 | In vitro CONCENTRATION100000 CFU/mL | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELBALB/c mice | In vivo CONCENTRATION60 mg/kg | In vivo MODE OF DELIVERYIntravenous | In vivo METHODFluorescence microscopy assay | In vivo RESULTIt crosses the BBB. | ACTIONIt shows intermediate susceptibility. | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONCombined with Vanomycin | PHYSICAL CONDITIONNA | RESPONSEMIC | RESULT6.3 ± 1.6 micromolar | LABELNA | PMID 30824786 |
| B3pdbIDb3pdb_0015 | PEPTIDE NAMETransportan 10 | PEPTIDE SEQUENCE (1-letter)AGYLLGKINLKALAALAKKIL | PEPTIDE SEQUENCE (3-letter)AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu | N-TERMINAL MODIFICATIONN-terminal Fmoc group was removed and the propiola | C-TERMINAL MODIFICATION Amide group is attached | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH21 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURECationic | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESN[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O | CELL LINES. aureus MRSA 12673 | In vitro CONCENTRATION100000 CFU/mL | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELBALB/c mice | In vivo CONCENTRATION60 mg/kg | In vivo MODE OF DELIVERYIntravenous | In vivo METHODFluorescence microscopy assay | In vivo RESULTIt crosses the BBB. | ACTIONIt shows intermediate susceptibility. | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONCombined with Vanomycin | PHYSICAL CONDITIONNA | RESPONSEMIC | RESULT1.6 ± 0.9 micromolar | LABELNA | PMID 30824786 |
| B3pdbIDb3pdb_0016 | PEPTIDE NAMETransportan 10 | PEPTIDE SEQUENCE (1-letter)AGYLLGKINLKALAALAKKIL | PEPTIDE SEQUENCE (3-letter)AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu | N-TERMINAL MODIFICATIONN-terminal Fmoc group was removed and the propiola | C-TERMINAL MODIFICATION Amide group is attached | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH21 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURECationic | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESN[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O | CELL LINES. aureus MRSA 12673 | In vitro CONCENTRATION100000 CFU/mL | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELBALB/c mice | In vivo CONCENTRATION60 mg/kg | In vivo MODE OF DELIVERYIntravenous | In vivo METHODFluorescence microscopy assay | In vivo RESULTIt crosses the BBB. | ACTIONIt shows intermediate susceptibility. | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONCombined with Vanomycin | PHYSICAL CONDITIONNA | RESPONSEMIC | RESULT1.6 ± 0.7 micromolar | LABELNA | PMID 30824786 |
| B3pdbIDb3pdb_0017 | PEPTIDE NAMETransportan 10 | PEPTIDE SEQUENCE (1-letter)AGYLLGKINLKALAALAKKIL | PEPTIDE SEQUENCE (3-letter)AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION Amide group is attached | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH21 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURECationic | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESN[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O | CELL LINES. aureus MRSA 12673 | In vitro CONCENTRATION100000 CFU/mL | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELBALB/c mice | In vivo CONCENTRATION60 mg/kg | In vivo MODE OF DELIVERYIntravenous | In vivo METHODFluorescence microscopy assay | In vivo RESULTIt crosses the BBB. | ACTIONIt shows high sensitivity | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONCombined with Vanomycin | PHYSICAL CONDITIONNA | RESPONSEMIC | RESULT0.8 ± 0.4 micromolar | LABELNA | PMID 30824786 |
| B3pdbIDb3pdb_0018 | PEPTIDE NAMETransportan 10 | PEPTIDE SEQUENCE (1-letter)AGYLLGKINLKALAALAKKIL | PEPTIDE SEQUENCE (3-letter)AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION Amide group is attached | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH21 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURECationic | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESN[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O | CELL LINES. aureus MRSA 12673 | In vitro CONCENTRATION100000 CFU/mL | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELBALB/c mice | In vivo CONCENTRATION60 mg/kg | In vivo MODE OF DELIVERYIntravenous | In vivo METHODFluorescence microscopy assay | In vivo RESULTIt crosses the BBB. | ACTIONIt shows high sensitivity | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONCombined with Vanomycin | PHYSICAL CONDITIONNA | RESPONSEMIC | RESULT0.8 ± 0.3 micromolar | LABELNA | PMID 30824786 |
| B3pdbIDb3pdb_0019 | PEPTIDE NAMETransportan 10 | PEPTIDE SEQUENCE (1-letter)AGYLLGKINLKALAALAKKIL | PEPTIDE SEQUENCE (3-letter)AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu | N-TERMINAL MODIFICATION6-carboxyfluorescein (Fl) was coupled to the N-ter | C-TERMINAL MODIFICATION Amide group is attached | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH21 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURECationic | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESN[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O | CELL LINES. aureus MRSA 12673 | In vitro CONCENTRATION100000 CFU/mL | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELBALB/c mice | In vivo CONCENTRATION60 mg/kg | In vivo MODE OF DELIVERYIntravenous | In vivo METHODFluorescence microscopy assay | In vivo RESULTIt crosses the BBB. | ACTIONIt shows high sensitivity | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONCombined with Vanomycin | PHYSICAL CONDITIONNA | RESPONSEMIC | RESULT0.8 ± 0.3 micromolar | LABELNA | PMID 30824786 |
| B3pdbIDb3pdb_0020 | PEPTIDE NAMETransportan 10 | PEPTIDE SEQUENCE (1-letter)AGYLLGKINLKALAALAKKIL | PEPTIDE SEQUENCE (3-letter)AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION Amide group is attached | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH21 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURECationic | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESN[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O | CELL LINES. aureus MRSA hetero-VISA 6347b | In vitro CONCENTRATION100000 CFU/mL | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELBALB/c mice | In vivo CONCENTRATION60 mg/kg | In vivo MODE OF DELIVERYIntravenous | In vivo METHODFluorescence microscopy assay | In vivo RESULTIt crosses the BBB. | ACTIONIt shows high sensitivity | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONCombined with Vanomycin | PHYSICAL CONDITIONNA | RESPONSEMIC | RESULT12.5 ± 3.2 micromolar | LABELNA | PMID 30824786 |
| B3pdbIDb3pdb_0021 | PEPTIDE NAMETransportan 10 | PEPTIDE SEQUENCE (1-letter)AGYLLGKINLKALAALAKKIL | PEPTIDE SEQUENCE (3-letter)AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu | N-TERMINAL MODIFICATIONN-terminal Fmoc group was removed and the propiola | C-TERMINAL MODIFICATION Amide group is attached | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH21 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURECationic | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESN[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O | CELL LINES. aureus MRSA hetero-VISA 6347b | In vitro CONCENTRATION100000 CFU/mL | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELBALB/c mice | In vivo CONCENTRATION60 mg/kg | In vivo MODE OF DELIVERYIntravenous | In vivo METHODFluorescence microscopy assay | In vivo RESULTIt crosses the BBB. | ACTIONIt shows intermediate susceptibility. | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONCombined with Vanomycin | PHYSICAL CONDITIONNA | RESPONSEMIC | RESULT1.6 ± 0.3 micromolar | LABELNA | PMID 30824786 |
| B3pdbIDb3pdb_0022 | PEPTIDE NAMETransportan 10 | PEPTIDE SEQUENCE (1-letter)AGYLLGKINLKALAALAKKIL | PEPTIDE SEQUENCE (3-letter)AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu | N-TERMINAL MODIFICATIONN-terminal Fmoc group was removed and the propiola | C-TERMINAL MODIFICATION Amide group is attached | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH21 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURECationic | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESN[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O | CELL LINES. aureus MRSA hetero-VISA 6347b | In vitro CONCENTRATION100000 CFU/mL | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELBALB/c mice | In vivo CONCENTRATION60 mg/kg | In vivo MODE OF DELIVERYIntravenous | In vivo METHODFluorescence microscopy assay | In vivo RESULTIt crosses the BBB. | ACTIONIt shows intermediate susceptibility. | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONCombined with Vanomycin | PHYSICAL CONDITIONNA | RESPONSEMIC | RESULT3.1 ± 0.8 micromolar | LABELNA | PMID 30824786 |
| B3pdbIDb3pdb_0023 | PEPTIDE NAMETransportan 10 | PEPTIDE SEQUENCE (1-letter)AGYLLGKINLKALAALAKKIL | PEPTIDE SEQUENCE (3-letter)AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION Amide group is attached | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH21 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURECationic | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESN[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O | CELL LINES. aureus MRSA hetero-VISA 6347b | In vitro CONCENTRATION100000 CFU/mL | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELBALB/c mice | In vivo CONCENTRATION60 mg/kg | In vivo MODE OF DELIVERYIntravenous | In vivo METHODFluorescence microscopy assay | In vivo RESULTIt crosses the BBB. | ACTIONIt shows intermediate susceptibility. | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONCombined with Vanomycin | PHYSICAL CONDITIONNA | RESPONSEMIC | RESULT1.6 ± 0.4 micromolar | LABELNA | PMID 30824786 |
| B3pdbIDb3pdb_0024 | PEPTIDE NAMETransportan 10 | PEPTIDE SEQUENCE (1-letter)AGYLLGKINLKALAALAKKIL | PEPTIDE SEQUENCE (3-letter)AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION Amide group is attached | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH21 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURECationic | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESN[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O | CELL LINES. aureus MRSA hetero-VISA 6347b | In vitro CONCENTRATION100000 CFU/mL | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELBALB/c mice | In vivo CONCENTRATION60 mg/kg | In vivo MODE OF DELIVERYIntravenous | In vivo METHODFluorescence microscopy assay | In vivo RESULTIt crosses the BBB. | ACTIONIt shows intermediate susceptibility. | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONCombined with Vanomycin | PHYSICAL CONDITIONNA | RESPONSEMIC | RESULT3.1 ± 0.8 micromolar | LABELNA | PMID 30824786 |
| B3pdbIDb3pdb_0025 | PEPTIDE NAMETransportan 10 | PEPTIDE SEQUENCE (1-letter)AGYLLGKINLKALAALAKKIL | PEPTIDE SEQUENCE (3-letter)AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu | N-TERMINAL MODIFICATION6-carboxyfluorescein (Fl) was coupled to the N-ter | C-TERMINAL MODIFICATION Amide group is attached | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH21 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURECationic | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESN[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O | CELL LINES. aureus MRSA hetero-VISA 6347b | In vitro CONCENTRATION100000 CFU/mL | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELBALB/c mice | In vivo CONCENTRATION60 mg/kg | In vivo MODE OF DELIVERYIntravenous | In vivo METHODFluorescence microscopy assay | In vivo RESULTIt crosses the BBB. | ACTIONIt shows intermediate susceptibility. | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONCombined with Vanomycin | PHYSICAL CONDITIONNA | RESPONSEMIC | RESULT3.1 ± 0.8 micromolar | LABELNA | PMID 30824786 |
| B3pdbIDb3pdb_0026 | PEPTIDE NAMETransportan 10 | PEPTIDE SEQUENCE (1-letter)AGYLLGKINLKALAALAKKIL | PEPTIDE SEQUENCE (3-letter)AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION Amide group is attached | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH21 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURECationic | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESN[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O | CELL LINEEnterococcus faecium 3934825 | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELBALB/c mice | In vivo CONCENTRATION60 mg/kg | In vivo MODE OF DELIVERYIntravenous | In vivo METHODFluorescence microscopy assay | In vivo RESULTIt crosses the BBB. | ACTIONIt shows intermediate susceptibility. | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONCombined with Vanomycin | PHYSICAL CONDITIONNA | RESPONSEMIC | RESULT12.5 ± 3.4 micromolar | LABELNA | PMID 30824786 |
| B3pdbIDb3pdb_0027 | PEPTIDE NAMETransportan 10 | PEPTIDE SEQUENCE (1-letter)AGYLLGKINLKALAALAKKIL | PEPTIDE SEQUENCE (3-letter)AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu | N-TERMINAL MODIFICATIONN-terminal Fmoc group was removed and the propiola | C-TERMINAL MODIFICATION Amide group is attached | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH21 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURECationic | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESN[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O | CELL LINEEnterococcus faecium 3934825 | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELBALB/c mice | In vivo CONCENTRATION60 mg/kg | In vivo MODE OF DELIVERYIntravenous | In vivo METHODFluorescence microscopy assay | In vivo RESULTIt crosses the BBB. | ACTIONIt shows the resistance | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONCombined with Vanomycin | PHYSICAL CONDITIONNA | RESPONSEMIC | RESULT50.0 ± 10.2 micromolar | LABELNA | PMID 30824786 |
| B3pdbIDb3pdb_0028 | PEPTIDE NAMETransportan 10 | PEPTIDE SEQUENCE (1-letter)AGYLLGKINLKALAALAKKIL | PEPTIDE SEQUENCE (3-letter)AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu | N-TERMINAL MODIFICATIONN-terminal Fmoc group was removed and the propiola | C-TERMINAL MODIFICATION Amide group is attached | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH21 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURECationic | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESN[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O | CELL LINEEnterococcus faecium 3934825 | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELBALB/c mice | In vivo CONCENTRATION60 mg/kg | In vivo MODE OF DELIVERYIntravenous | In vivo METHODFluorescence microscopy assay | In vivo RESULTIt crosses the BBB. | ACTIONIt shows the resistance | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONCombined with Vanomycin | PHYSICAL CONDITIONNA | RESPONSEMIC | RESULT25.0 ± 5.1 micromolar | LABELNA | PMID 30824786 |
| B3pdbIDb3pdb_0029 | PEPTIDE NAMETransportan 10 | PEPTIDE SEQUENCE (1-letter)AGYLLGKINLKALAALAKKIL | PEPTIDE SEQUENCE (3-letter)AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION Amide group is attached | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH21 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURECationic | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESN[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O | CELL LINEEnterococcus faecium 3934825 | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELBALB/c mice | In vivo CONCENTRATION60 mg/kg | In vivo MODE OF DELIVERYIntravenous | In vivo METHODFluorescence microscopy assay | In vivo RESULTIt crosses the BBB. | ACTIONIt shows intermediate susceptibility. | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONCombined with Vanomycin | PHYSICAL CONDITIONNA | RESPONSEMIC | RESULT12.5 ± 3.2 micromolar | LABELNA | PMID 30824786 |
| B3pdbIDb3pdb_0030 | PEPTIDE NAMETransportan 10 | PEPTIDE SEQUENCE (1-letter)AGYLLGKINLKALAALAKKIL | PEPTIDE SEQUENCE (3-letter)AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION Amide group is attached | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH21 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURECationic | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESN[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O | CELL LINEEnterococcus faecium 3934825 | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELBALB/c mice | In vivo CONCENTRATION60 mg/kg | In vivo MODE OF DELIVERYIntravenous | In vivo METHODFluorescence microscopy assay | In vivo RESULTIt crosses the BBB. | ACTIONIt shows intermediate susceptibility. | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONCombined with Vanomycin | PHYSICAL CONDITIONNA | RESPONSEMIC | RESULT6.3 ± 1.7 micromolar | LABELNA | PMID 30824786 |
| B3pdbIDb3pdb_0031 | PEPTIDE NAMETransportan 10 | PEPTIDE SEQUENCE (1-letter)AGYLLGKINLKALAALAKKIL | PEPTIDE SEQUENCE (3-letter)AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu | N-TERMINAL MODIFICATION6-carboxyfluorescein (Fl) was coupled to the N-ter | C-TERMINAL MODIFICATION Amide group is attached | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH21 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURECationic | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESN[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O | CELL LINEEnterococcus faecium 3934825 | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELBALB/c mice | In vivo CONCENTRATION60 mg/kg | In vivo MODE OF DELIVERYIntravenous | In vivo METHODFluorescence microscopy assay | In vivo RESULTIt crosses the BBB. | ACTIONIt shows intermediate susceptibility. | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONCombined with Vanomycin | PHYSICAL CONDITIONNA | RESPONSEMIC | RESULT6.3 ± 1.7 micromolar | LABELNA | PMID 30824786 |
| B3pdbIDb3pdb_0032 | PEPTIDE NAMETransportan 10 | PEPTIDE SEQUENCE (1-letter)AGYLLGKINLKALAALAKKIL | PEPTIDE SEQUENCE (3-letter)AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION Amide group is attached | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH21 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURECationic | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESN[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O | CELL LINEEnterococcus faecalis 3937158 | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELBALB/c mice | In vivo CONCENTRATION60 mg/kg | In vivo MODE OF DELIVERYIntravenous | In vivo METHODFluorescence microscopy assay | In vivo RESULTIt crosses the BBB. | ACTIONIt shows intermediate susceptibility. | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONCombined with Vanomycin | PHYSICAL CONDITIONNA | RESPONSEMIC | RESULT12.5 ± 2.2 micromolar | LABELNA | PMID 30824786 |
| B3pdbIDb3pdb_0033 | PEPTIDE NAMETransportan 10 | PEPTIDE SEQUENCE (1-letter)AGYLLGKINLKALAALAKKIL | PEPTIDE SEQUENCE (3-letter)AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu | N-TERMINAL MODIFICATIONN-terminal Fmoc group was removed and the propiola | C-TERMINAL MODIFICATION Amide group is attached | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH21 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURECationic | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESN[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O | CELL LINEEnterococcus faecalis 3937158 | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELBALB/c mice | In vivo CONCENTRATION60 mg/kg | In vivo MODE OF DELIVERYIntravenous | In vivo METHODFluorescence microscopy assay | In vivo RESULTIt crosses the BBB. | ACTIONIt shows intermediate susceptibility. | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONCombined with Vanomycin | PHYSICAL CONDITIONNA | RESPONSEMIC | RESULT6.3 ± 1.6 micromolar | LABELNA | PMID 30824786 |
| B3pdbIDb3pdb_0034 | PEPTIDE NAMETransportan 10 | PEPTIDE SEQUENCE (1-letter)AGYLLGKINLKALAALAKKIL | PEPTIDE SEQUENCE (3-letter)AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu | N-TERMINAL MODIFICATIONN-terminal Fmoc group was removed and the propiola | C-TERMINAL MODIFICATION Amide group is attached | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH21 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURECationic | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESN[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O | CELL LINEEnterococcus faecalis 3937158 | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELBALB/c mice | In vivo CONCENTRATION60 mg/kg | In vivo MODE OF DELIVERYIntravenous | In vivo METHODFluorescence microscopy assay | In vivo RESULTIt crosses the BBB. | ACTIONIt shows the resistance | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONCombined with Vanomycin | PHYSICAL CONDITIONNA | RESPONSEMIC | RESULT25.0 ± 6.5 micromolar | LABELNA | PMID 30824786 |
| B3pdbIDb3pdb_0035 | PEPTIDE NAMETransportan 10 | PEPTIDE SEQUENCE (1-letter)AGYLLGKINLKALAALAKKIL | PEPTIDE SEQUENCE (3-letter)AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION Amide group is attached | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH21 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURECationic | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESN[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O | CELL LINEEnterococcus faecalis 3937158 | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELBALB/c mice | In vivo CONCENTRATION60 mg/kg | In vivo MODE OF DELIVERYIntravenous | In vivo METHODFluorescence microscopy assay | In vivo RESULTIt crosses the BBB. | ACTIONIt shows the resistance | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONCombined with Vanomycin | PHYSICAL CONDITIONNA | RESPONSEMIC | RESULT25.0 ± 5.1 micromolar | LABELNA | PMID 30824786 |
| B3pdbIDb3pdb_0036 | PEPTIDE NAMETransportan 10 | PEPTIDE SEQUENCE (1-letter)AGYLLGKINLKALAALAKKIL | PEPTIDE SEQUENCE (3-letter)AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION Amide group is attached | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH21 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURECationic | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESN[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O | CELL LINEEnterococcus faecalis 3937158 | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELBALB/c mice | In vivo CONCENTRATION60 mg/kg | In vivo MODE OF DELIVERYIntravenous | In vivo METHODFluorescence microscopy assay | In vivo RESULTIt crosses the BBB. | ACTIONIt shows the resistance | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONCombined with Vanomycin | PHYSICAL CONDITIONNA | RESPONSEMIC | RESULT25.0 ± 6.9 micromolar | LABELNA | PMID 30824786 |
| B3pdbIDb3pdb_0037 | PEPTIDE NAMETransportan 10 | PEPTIDE SEQUENCE (1-letter)AGYLLGKINLKALAALAKKIL | PEPTIDE SEQUENCE (3-letter)AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu | N-TERMINAL MODIFICATION6-carboxyfluorescein (Fl) was coupled to the N-ter | C-TERMINAL MODIFICATION Amide group is attached | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH21 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURECationic | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESN[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O | CELL LINEEnterococcus faecalis 3937158 | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELBALB/c mice | In vivo CONCENTRATION60 mg/kg | In vivo MODE OF DELIVERYIntravenous | In vivo METHODFluorescence microscopy assay | In vivo RESULTIt crosses the BBB. | ACTIONIt shows the resistance | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONCombined with Vanomycin | PHYSICAL CONDITIONNA | RESPONSEMIC | RESULT25.0 ± 6.9 micromolar | LABELNA | PMID 30824786 |
| B3pdbIDb3pdb_0047 | PEPTIDE NAMEC-TN-APNPs | PEPTIDE SEQUENCE (1-letter)CAQK | PEPTIDE SEQUENCE (3-letter)CysAlaGlnLys | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH4 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESN[C@@]([H])(CS)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCC(=O)N)C(=O)N[C@@]([H])(CCCCN)C(=O)O | CELL LINEhCMEC/D3 and NHA cells | In vitro CONCENTRATIONNA | In vitro METHODTEM imaging | In vitro RESULTResponsive to thrombin cleavage, reduced the cytotoxicity of Tat-NR2B9c, and increased BBB permeabil | ANIMAL MODELC57BL6 mice | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYIntravenous | In vivo METHODDynamic light scattering | In vivo RESULTBetter circulation time, better targeting ability and penetrating efficiency to the injured brain, a | ACTIONTreatment reduced the injury size | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONCombined with Tat-NR2B9c | PHYSICAL CONDITIONTraumatic brain injury | RESPONSENA | RESULTNA | LABELNA | PMID 31213815 |
| B3pdbIDb3pdb_0048 | PEPTIDE NAMECC-TN-APNPs | PEPTIDE SEQUENCE (1-letter)CCAQK | PEPTIDE SEQUENCE (3-letter)CysCysAlaGlnLys | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH5 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESN[C@@]([H])(CS)C(=O)N[C@@]([H])(CS)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCC(=O)N)C(=O)N[C@@]([H])(CCCCN)C(=O)O | CELL LINEhCMEC/D3 and NHA cells | In vitro CONCENTRATIONNA | In vitro METHODTEM imaging | In vitro RESULTResponsive to thrombin cleavage, reduced the cytotoxicity of Tat-NR2B9c, and increased BBB permeabil | ANIMAL MODELC57BL6 mice | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYIntravenous | In vivo METHODDynamic light scattering | In vivo RESULTBetter circulation time, better targeting ability and penetrating efficiency to the injured brain, a | ACTIONTreatment reduced the injury size | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONCombined with Tat-NR2B9c | PHYSICAL CONDITIONTraumatic brain injury | RESPONSENA | RESULTNA | LABELNA | PMID 31213815 |
| B3pdbIDb3pdb_0049 | PEPTIDE NAMEgH625Cys | PEPTIDE SEQUENCE (1-letter)HGLASTLTRWAHYNALIRAF | PEPTIDE SEQUENCE (3-letter)HisGlyLeuAlaSerThrLeuThrArgTrpAlaHisTyrAsnAlaLeuIleArgAlaPhe | N-TERMINAL MODIFICATIONAcetylaed at N-terminal | C-TERMINAL MODIFICATION Cys-CONH2 group is attached at C-terminal | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH21 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESN[C@@]([H])(CC1=CN=C-N1)C(=O)NCC(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CO)C(=O)N[C@@]([H])([C@]([H])(O)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])([C@]([H])(O)C)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CC(=CN2)C1=C2C=CC=C1)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC1=CN=C-N1)C(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(Cc1ccccc1)C(=O)O | CELL LINEBMECs | In vitro CONCENTRATION5 micromolar | In vitro METHODFluorescence microscopy | In vitro RESULTLiposomes preparations were non-toxic for the endothelial cells and improves the transfer of liposom | ANIMAL MODELMouse | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYIntravenous | In vivo METHODFluorescence microscopy | In vivo RESULTgH625 ameliorates the efficiency of liposomes to deliver. PACAP | ACTIONgH625-liposomes represent a promising strategy to deliver therapeutic agents to CNS and to provide a | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONComined with liposome | PHYSICAL CONDITIONNA | RESPONSENA | RESULTNA | LABELNA | PMID 31235716 |
| B3pdbIDb3pdb_0050 | PEPTIDE NAMEDeltorphan | PEPTIDE SEQUENCE (1-letter)YAFDVVG | PEPTIDE SEQUENCE (3-letter)Tyr-(D)Ala-Phe-Asp-Val-Val-Gly-NH2 | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION Amide group is attached | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH7 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESN[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(Cc1ccccc1)C(=O)N[C@@]([H])(CC(=O)O)C(=O)N[C@@]([H])(C(C)C)C(=O)N[C@@]([H])(C(C)C)C(=O)NCC(=O)O | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELC57BL6 mice | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYIntravenous | In vivo METHODConfocal microscopy | In vivo RESULTPresence of engineered nano particles within the brain parenchyma with particular focus on hippocamp | ACTIONOpioid-derived peptides featured by specific helix-like conformation as possible ligands to engineer | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONCNS parenchyma | COMBINATIONComined | PHYSICAL CONDITIONNA | RESPONSENA | RESULTNA | LABELNA | PMID 32479916 |
| B3pdbIDb3pdb_0051 | PEPTIDE NAMESLS | PEPTIDE SEQUENCE (1-letter)SLSHSPQ | PEPTIDE SEQUENCE (3-letter)SerLeuSerHisSerProGln | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH7 | PEPTIDE CONFORMATIONCyclic | PEPTIDE NATURENeutral | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESN[C@@]([H])(CO)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CO)C(=O)N[C@@]([H])(CC1=CN=C-N1)C(=O)N[C@@]([H])(CO)C(=O)N1[C@@]([H])(CCC1)C(=O)N[C@@]([H])(CCC(=O)N)C(=O)O | CELL LINEhCMEC/D3 cell monolayers | In vitro CONCENTRATION200000 cells per well | In vitro METHODConfocal microscopy | In vitro RESULTIt promoted phage permeation across the hCMEC/D3 cell monolayer. | ANIMAL MODELMice | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYIntravenous | In vivo METHODPlaque formation assay | In vivo RESULTCyclic SLS peptide facilitated phage permeation across the mouse BBB in vivo | ACTIONBBB-permeable cyclic SLS heptapeptide for brain delivery of macromolecules via macropinocytosis and | TRANSPORT TYPEMacropinocytosis | SUBCELLULAR LOCALISATIONBrain parenchyma | COMBINATIONCombined with M13 phage | PHYSICAL CONDITIONNA | RESPONSENA | RESULTNA | LABELNA | PMID 32135226 |
| B3pdbIDb3pdb_0080 | PEPTIDE NAMEBVDO2 | PEPTIDE SEQUENCE (1-letter)DmtNmeAFS-NH2 | PEPTIDE SEQUENCE (3-letter)H-Dmt-Nme-D-Ala-Phe-Ser-NH2 | N-TERMINAL MODIFICATIONMethylation | C-TERMINAL MODIFICATION Amidation | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH4 | PEPTIDE CONFORMATIONTetrapeptide | PEPTIDE NATURECationic | SOURCE/ORIGIN OF PEPTIDENA | SMILESNA | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELC57BL6 mice | In vivo CONCENTRATION5 mg/Kg | In vivo MODE OF DELIVERYIntravenous | In vivo METHODHot water tail flick test | In vivo RESULT70% maximum possible effect after 5 minutes | ACTIONCross BBB and shows morphine like action with analgesic effects | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSENA | RESULTNA | LABELNA | PMID 22289619 |
| B3pdbIDb3pdb_0081 | PEPTIDE NAMEBVDO2 | PEPTIDE SEQUENCE (1-letter)DmtNmeAFS-NH3 | PEPTIDE SEQUENCE (3-letter)H-Dmt-Nme-D-Ala-Phe-Ser-NH2 | N-TERMINAL MODIFICATIONMethylation | C-TERMINAL MODIFICATION Amidation | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH4 | PEPTIDE CONFORMATIONTetrapeptide | PEPTIDE NATURECationic | SOURCE/ORIGIN OF PEPTIDENA | SMILESNA | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELC57BL6 mice | In vivo CONCENTRATION5 mg/Kg | In vivo MODE OF DELIVERYIntravenous | In vivo METHODHot water tail flick test | In vivo RESULT100% maximum possible effect after 15 minutes | ACTIONCross BBB and shows morphine like action with analgesic effects | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSENA | RESULTNA | LABELNA | PMID 22289619 |
| B3pdbIDb3pdb_0082 | PEPTIDE NAMEBVDO2 | PEPTIDE SEQUENCE (1-letter)DmtNmeAFS-NH4 | PEPTIDE SEQUENCE (3-letter)H-Dmt-Nme-D-Ala-Phe-Ser-NH2 | N-TERMINAL MODIFICATIONMethylation | C-TERMINAL MODIFICATION Amidation | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH4 | PEPTIDE CONFORMATIONTetrapeptide | PEPTIDE NATURECationic | SOURCE/ORIGIN OF PEPTIDENA | SMILESNA | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELC57BL6 mice | In vivo CONCENTRATION5 mg/Kg | In vivo MODE OF DELIVERYIntravenous | In vivo METHODHot water tail flick test | In vivo RESULT100% maximum possible effect after 30 minutes | ACTIONCross BBB and shows morphine like action with analgesic effects | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSENA | RESULTNA | LABELNA | PMID 22289619 |
| B3pdbIDb3pdb_0083 | PEPTIDE NAMEBVDO2 | PEPTIDE SEQUENCE (1-letter)DmtNmeAFS-NH5 | PEPTIDE SEQUENCE (3-letter)H-Dmt-Nme-D-Ala-Phe-Ser-NH2 | N-TERMINAL MODIFICATIONMethylation | C-TERMINAL MODIFICATION Amidation | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH4 | PEPTIDE CONFORMATIONTetrapeptide | PEPTIDE NATURECationic | SOURCE/ORIGIN OF PEPTIDENA | SMILESNA | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELC57BL6 mice | In vivo CONCENTRATION5 mg/Kg | In vivo MODE OF DELIVERYIntravenous | In vivo METHODHot water tail flick test | In vivo RESULT100% maximum possible effect after 60 minutes | ACTIONCross BBB and shows morphine like action with analgesic effects | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSENA | RESULTNA | LABELNA | PMID 22289619 |
| B3pdbIDb3pdb_0084 | PEPTIDE NAMEBVDO2 | PEPTIDE SEQUENCE (1-letter)DmtNmeAFS-NH6 | PEPTIDE SEQUENCE (3-letter)H-Dmt-Nme-D-Ala-Phe-Ser-NH2 | N-TERMINAL MODIFICATIONMethylation | C-TERMINAL MODIFICATION Amidation | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH4 | PEPTIDE CONFORMATIONTetrapeptide | PEPTIDE NATURECationic | SOURCE/ORIGIN OF PEPTIDENA | SMILESNA | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELC57BL6 mice | In vivo CONCENTRATION5 mg/Kg | In vivo MODE OF DELIVERYIntravenous | In vivo METHODHot water tail flick test | In vivo RESULT100% maximum possible effect after 120 minutes | ACTIONCross BBB and shows morphine like action with analgesic effects | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSENA | RESULTNA | LABELNA | PMID 22289619 |
| B3pdbIDb3pdb_0085 | PEPTIDE NAMEBVDO2 | PEPTIDE SEQUENCE (1-letter)DmtNmeAFS-NH7 | PEPTIDE SEQUENCE (3-letter)H-Dmt-Nme-D-Ala-Phe-Ser-NH2 | N-TERMINAL MODIFICATIONMethylation | C-TERMINAL MODIFICATION Amidation | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH4 | PEPTIDE CONFORMATIONTetrapeptide | PEPTIDE NATURECationic | SOURCE/ORIGIN OF PEPTIDENA | SMILESNA | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELC57BL6 mice | In vivo CONCENTRATION1 mg/Kg | In vivo MODE OF DELIVERYIntravenous | In vivo METHODHot water tail flick test | In vivo RESULT40% maximum possible effect after 5 minutes | ACTIONCross BBB and shows morphine like action with analgesic effects | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSENA | RESULTNA | LABELNA | PMID 22289619 |
| B3pdbIDb3pdb_0086 | PEPTIDE NAMEBVDO2 | PEPTIDE SEQUENCE (1-letter)DmtNmeAFS-NH8 | PEPTIDE SEQUENCE (3-letter)H-Dmt-Nme-D-Ala-Phe-Ser-NH2 | N-TERMINAL MODIFICATIONMethylation | C-TERMINAL MODIFICATION Amidation | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH4 | PEPTIDE CONFORMATIONTetrapeptide | PEPTIDE NATURECationic | SOURCE/ORIGIN OF PEPTIDENA | SMILESNA | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELC57BL6 mice | In vivo CONCENTRATION1 mg/Kg | In vivo MODE OF DELIVERYIntravenous | In vivo METHODHot water tail flick test | In vivo RESULT80% maximum possible effect after 15 minutes | ACTIONCross BBB and shows morphine like action with analgesic effects | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSENA | RESULTNA | LABELNA | PMID 22289619 |
| B3pdbIDb3pdb_0087 | PEPTIDE NAMEBVDO2 | PEPTIDE SEQUENCE (1-letter)DmtNmeAFS-NH9 | PEPTIDE SEQUENCE (3-letter)H-Dmt-Nme-D-Ala-Phe-Ser-NH2 | N-TERMINAL MODIFICATIONMethylation | C-TERMINAL MODIFICATION Amidation | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH4 | PEPTIDE CONFORMATIONTetrapeptide | PEPTIDE NATURECationic | SOURCE/ORIGIN OF PEPTIDENA | SMILESNA | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELC57BL6 mice | In vivo CONCENTRATION1 mg/Kg | In vivo MODE OF DELIVERYIntravenous | In vivo METHODHot water tail flick test | In vivo RESULT80% maximum possible effect after 30 minutes | ACTIONCross BBB and shows morphine like action with analgesic effects | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSENA | RESULTNA | LABELNA | PMID 22289619 |
| B3pdbIDb3pdb_0088 | PEPTIDE NAMEBVDO2 | PEPTIDE SEQUENCE (1-letter)DmtNmeAFS-NH10 | PEPTIDE SEQUENCE (3-letter)H-Dmt-Nme-D-Ala-Phe-Ser-NH2 | N-TERMINAL MODIFICATIONMethylation | C-TERMINAL MODIFICATION Amidation | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH4 | PEPTIDE CONFORMATIONTetrapeptide | PEPTIDE NATURECationic | SOURCE/ORIGIN OF PEPTIDENA | SMILESNA | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELC57BL6 mice | In vivo CONCENTRATION1 mg/Kg | In vivo MODE OF DELIVERYIntravenous | In vivo METHODHot water tail flick test | In vivo RESULT90% maximum possible effect after 60 minutes | ACTIONCross BBB and shows morphine like action with analgesic effects | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSENA | RESULTNA | LABELNA | PMID 22289619 |
| B3pdbIDb3pdb_0089 | PEPTIDE NAMEBVDO2 | PEPTIDE SEQUENCE (1-letter)DmtNmeAFS-NH11 | PEPTIDE SEQUENCE (3-letter)H-Dmt-Nme-D-Ala-Phe-Ser-NH2 | N-TERMINAL MODIFICATIONMethylation | C-TERMINAL MODIFICATION Amidation | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH4 | PEPTIDE CONFORMATIONTetrapeptide | PEPTIDE NATURECationic | SOURCE/ORIGIN OF PEPTIDENA | SMILESNA | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELC57BL6 mice | In vivo CONCENTRATION1 mg/Kg | In vivo MODE OF DELIVERYIntravenous | In vivo METHODHot water tail flick test | In vivo RESULT100% maximum possible effect after 120 minutes | ACTIONCross BBB and shows morphine like action with analgesic effects | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSENA | RESULTNA | LABELNA | PMID 22289619 |
| B3pdbIDb3pdb_0090 | PEPTIDE NAMEBVDO2 | PEPTIDE SEQUENCE (1-letter)DmtNmeAFS-NH12 | PEPTIDE SEQUENCE (3-letter)H-Dmt-Nme-D-Ala-Phe-Ser-NH2 | N-TERMINAL MODIFICATIONMethylation | C-TERMINAL MODIFICATION Amidation | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH4 | PEPTIDE CONFORMATIONTetrapeptide | PEPTIDE NATURECationic | SOURCE/ORIGIN OF PEPTIDENA | SMILESNA | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELC57BL6 mice | In vivo CONCENTRATION0.5 mg/Kg | In vivo MODE OF DELIVERYIntravenous | In vivo METHODHot water tail flick test | In vivo RESULT10% maximum possible effect after 5 minutes | ACTIONCross BBB and shows morphine like action with analgesic effects | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSENA | RESULTNA | LABELNA | PMID 22289619 |
| B3pdbIDb3pdb_0091 | PEPTIDE NAMEBVDO2 | PEPTIDE SEQUENCE (1-letter)DmtNmeAFS-NH13 | PEPTIDE SEQUENCE (3-letter)H-Dmt-Nme-D-Ala-Phe-Ser-NH2 | N-TERMINAL MODIFICATIONMethylation | C-TERMINAL MODIFICATION Amidation | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH4 | PEPTIDE CONFORMATIONTetrapeptide | PEPTIDE NATURECationic | SOURCE/ORIGIN OF PEPTIDENA | SMILESNA | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELC57BL6 mice | In vivo CONCENTRATION0.5 mg/Kg | In vivo MODE OF DELIVERYIntravenous | In vivo METHODHot water tail flick test | In vivo RESULT40% maximum possible effect after 15 minutes | ACTIONCross BBB and shows morphine like action with analgesic effects | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSENA | RESULTNA | LABELNA | PMID 22289619 |
| B3pdbIDb3pdb_0092 | PEPTIDE NAMEBVDO2 | PEPTIDE SEQUENCE (1-letter)DmtNmeAFS-NH14 | PEPTIDE SEQUENCE (3-letter)H-Dmt-Nme-D-Ala-Phe-Ser-NH2 | N-TERMINAL MODIFICATIONMethylation | C-TERMINAL MODIFICATION Amidation | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH4 | PEPTIDE CONFORMATIONTetrapeptide | PEPTIDE NATURECationic | SOURCE/ORIGIN OF PEPTIDENA | SMILESNA | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELC57BL6 mice | In vivo CONCENTRATION0.5 mg/Kg | In vivo MODE OF DELIVERYIntravenous | In vivo METHODHot water tail flick test | In vivo RESULT70% maximum possible effect after 30 minutes | ACTIONCross BBB and shows morphine like action with analgesic effects | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSENA | RESULTNA | LABELNA | PMID 22289619 |